Advancing cannabinoid-based and targeted therapies for the treatment of coronavirus and cancer
Pascal Biosciences is dedicated to improving the lives of patients suffering from life-threatening diseases including COVID-19 and intractable cancers such as glioblastoma. We are developing novel cannabinoid-based small molecules and targeted antibodies, focusing on treatments for SAR-CoV-2 infection and cancers for which there are no adequate therapies.
Cannabinoid for COVID-19
In a cell-based assay, Pascal has identified a cannabinoid that blocks SARS-CoV-2 with a potency similar to remdesivir.
PAS-403 is a cannabinoid-based small molecule that utilizes a unique mechanism of action to kill cancer cells. Clinical trials are targeted to begin in 2021.
Pascal Biosciences (TSX-V:PAS, FSE:6PB.F, OTC:PSCBF) is a biopharmaceutical company focused on advancing innovative approaches for the treatment of cancer.